Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Blood (2024) 143 (13): 1259–1268.

https://doi.org/10.1182/blood.2023022399

Published: 2024

Includes: Supplemental data

Journal Articles

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Jahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, Oliver Charles Cohen, Darren Foard, Ana Martinez - Naharro, Lucia Venneri, Marianna Fontana, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh D. Wechalekar

Blood (2023) 142 (Supplement 1): 537.

https://doi.org/10.1182/blood-2023-178243

Published: 2023

Journal Articles

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2022) 140 (Supplement 1): 2351–2353.

https://doi.org/10.1182/blood-2022-160018

Published: 2022

Journal Articles

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Ananth Sathyanath, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Sajitha Sachchithanantham, MBBS, BSc, FRCPath, Shameem Mahmood, Ana Martinez-Naharro, Marianna Fontana, Carol Whelan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137036

Published: 2020

Journal Articles

The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

Oliver C Cohen, MBBS, BSc, FRCPath, Andreia Ismael, Richa Manwani, MBBS, FRCPath, BSc, Sriram Ravichandran, MBBS, MRCP, FRCPath, Steven Law, MBBS, BSc, Darren Foard, Ana Martinez-Naharro, Shameem Mahmood, Sajitha Sachchithananthan, Philip N Hawkins, Helen J Lachmann, Julian D Gillmore, Marianna Fontana, Rodney H Falk, MD, Carol Whelan, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-137391

Published: 2020

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Faye Sharpley, Tamer Rezk, Thirusha Lane, Cristina Quarta, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (7): 761–764.

https://doi.org/10.1182/blood-2018-04-846493

Published: 2018

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Richa Manwani, MBBS, FRCPath, BSc, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, BSc,FRCPath,MBBS,MRCP, Marianna Fontana, Carol Whelan, Candida Quarta, Thirusha Lane, Helen Lachmann, Julian Gillmore, Philip Hawkins, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2017) 130 (Supplement 1): 1816.

https://doi.org/10.1182/blood.V130.Suppl_1.1816.1816

Published: 2017

Journal Articles

Natural history and outcome of light chain deposition disease

Rabya H. Sayed, Ashutosh D. Wechalekar, Janet A. Gilbertson, Paul Bass, Shameem Mahmood, Sajitha Sachchithanantham, Marianna Fontana, Ketna Patel, Carol J. Whelan, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore

Blood (2015) 126 (26): 2805–2810.

https://doi.org/10.1182/blood-2015-07-658872

Published: 2015

Includes: Supplemental data

Journal Articles

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MDFRCP, Helen Lachmann, MDFRCP, Marianna Fontana, MD, Shameem Mahmood, FRCPath, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 732.

https://doi.org/10.1182/blood.V126.23.732.732

Published: 2015

Journal Articles

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Mark B Pepys, MDPhDFRS FMedSci, Louise M Cookson, BSc, Sharon V Barton, BSc MSc, Alienor C Berges, PharmD, Thirusha Lane, RN MSc, David Hutt, BAppSc, Marianna Fontana, MD, James C Moon, MD, Julian D Gillmore, MDPhDFRCP, Ashutosh Wechalekar, MDFRCPath FRCP, Philip N Hawkins, MDPhDFMedSci, Duncan B Richards, DM FRCP

Blood (2015) 126 (23): 1836.

https://doi.org/10.1182/blood.V126.23.1836.1836

Published: 2015

Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 5357.

https://doi.org/10.1182/blood.V126.23.5357.5357

Published: 2015

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

NARROW

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis

The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

The UK Experience of Renal Transplantation in AL Amyloidosis

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study

Natural history and outcome of light chain deposition disease

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only